Clinical Trials Directory

Trials / Terminated

TerminatedNCT00651482

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Sandy Srinivas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer

Conditions

Interventions

TypeNameDescription
DRUGEverolimus
DRUGBevacizumab

Timeline

Start date
2008-08-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2008-04-02
Last updated
2017-04-11
Results posted
2014-07-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00651482. Inclusion in this directory is not an endorsement.

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) (NCT00651482) · Clinical Trials Directory